181 related articles for article (PubMed ID: 37523707)
21. Efficacy of Rituximab and Plasma Exchange in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis with Severe Kidney Disease.
Casal Moura M; Irazabal MV; Eirin A; Zand L; Sethi S; Borah BJ; Winters JL; Moriarty JP; Cartin-Ceba R; Berti A; Baqir M; Thompson GE; Makol A; Warrington KJ; Thao V; Specks U; Fervenza FC
J Am Soc Nephrol; 2020 Nov; 31(11):2688-2704. PubMed ID: 32826324
[TBL] [Abstract][Full Text] [Related]
22. Non-corticosteroid immunosuppressive medications for steroid-sensitive nephrotic syndrome in children.
Larkins NG; Liu ID; Willis NS; Craig JC; Hodson EM
Cochrane Database Syst Rev; 2020 Apr; 4(4):CD002290. PubMed ID: 32297308
[TBL] [Abstract][Full Text] [Related]
23. Cyclophosphamide followed by rituximab for aggressive multiple-relapsing antineutrophil cytoplasmic antibody-associated vasculitis.
Lionaki S; Fragoulis GE; Venetsanopoulou A; Vlachoyiannopoulos P; Boletis JN; Tzioufas AG
Clin Exp Rheumatol; 2017; 35 Suppl 103(1):155-164. PubMed ID: 28134075
[TBL] [Abstract][Full Text] [Related]
24. Maintenance therapy with azathioprine prolonged duration of remission for pemphigus patients who received rituximab as first-line or add-on therapy.
Cho YT; Huang YM; Wang LF; Chu CY
J Formos Med Assoc; 2020 Jan; 119(1 Pt 2):230-237. PubMed ID: 31103376
[TBL] [Abstract][Full Text] [Related]
25. Novel Therapies for ANCA-associated Vasculitis.
Monti S; Brandolino F; Milanesi A; Xoxi B; Delvino P; Montecucco C
Curr Rheumatol Rep; 2021 Apr; 23(6):38. PubMed ID: 33909172
[TBL] [Abstract][Full Text] [Related]
26. Reduced-dose versus high-dose glucocorticoids added to rituximab on remission induction in ANCA-associated vasculitis: predefined 2-year follow-up study.
Furuta S; Nakagomi D; Kobayashi Y; Hiraguri M; Sugiyama T; Amano K; Umibe T; Kono H; Kurasawa K; Kita Y; Matsumura R; Kaneko Y; Ninagawa K; Hiromura K; Kagami SI; Inaba Y; Hanaoka H; Ikeda K; Nakajima H;
Ann Rheum Dis; 2024 Jan; 83(1):96-102. PubMed ID: 37734880
[TBL] [Abstract][Full Text] [Related]
27. Comparison of individually tailored versus fixed-schedule rituximab regimen to maintain ANCA-associated vasculitis remission: results of a multicentre, randomised controlled, phase III trial (MAINRITSAN2).
Charles P; Terrier B; Perrodeau É; Cohen P; Faguer S; Huart A; Hamidou M; Agard C; Bonnotte B; Samson M; Karras A; Jourde-Chiche N; Lifermann F; Gobert P; Hanrotel-Saliou C; Godmer P; Martin-Silva N; Pugnet G; Matignon M; Aumaitre O; Viallard JF; Maurier F; Meaux-Ruault N; Rivière S; Sibilia J; Puéchal X; Ravaud P; Mouthon L; Guillevin L;
Ann Rheum Dis; 2018 Aug; 77(8):1143-1149. PubMed ID: 29695500
[TBL] [Abstract][Full Text] [Related]
28. Comparative efficacy and safety of rituximab, mycophenolate, methotrexate, and cyclophosphamide versus azathioprine as maintenance therapy in antineutrophil cytoplasmic antibody-associated vasculitis: A Bayesian network meta-analysis of randomized controlled trials.
Lee YH; Song GG
Int J Clin Pharmacol Ther; 2022 Feb; 60(2):97-105. PubMed ID: 34622770
[TBL] [Abstract][Full Text] [Related]
29. Interventions for renal vasculitis in adults.
Walters GD; Willis NS; Cooper TE; Craig JC
Cochrane Database Syst Rev; 2020 Jan; 1(1):CD003232. PubMed ID: 31927782
[TBL] [Abstract][Full Text] [Related]
30. The Pharmacogenomic Association of Fcγ Receptors and Cytochrome P450 Enzymes With Response to Rituximab or Cyclophosphamide Treatment in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.
Cartin-Ceba R; Indrakanti D; Specks U; Stone JH; Hoffman GS; Kallenberg CG; Langford CA; Merkel PA; Spiera RF; Monach PA; St Clair EW; Seo P; Tchao NK; Ytterberg SR; Brunetta PG; Song H; Birmingham D; Rovin BH;
Arthritis Rheumatol; 2017 Jan; 69(1):169-175. PubMed ID: 27482943
[TBL] [Abstract][Full Text] [Related]
31. Positive classic antineutrophil cytoplasmic antibody (C-ANCA) titer at switch to azathioprine therapy associated with relapse in proteinase 3-related vasculitis.
Slot MC; Tervaert JW; Boomsma MM; Stegeman CA
Arthritis Rheum; 2004 Apr; 51(2):269-73. PubMed ID: 15077271
[TBL] [Abstract][Full Text] [Related]
32. Clinical trials. Rituximab for maintenance of remission in AAV.
Tanna A; Pusey C
Nat Rev Nephrol; 2015 Mar; 11(3):131-2. PubMed ID: 25599619
[TBL] [Abstract][Full Text] [Related]
33. The evolving treatment of ANCA-associated vasculitides.
Sauranen J; Salmela A; Kahlos K; Antonen J; Ekstrand A; Pettersson T
Duodecim; 2016; 132(16):1449-55. PubMed ID: 29188932
[TBL] [Abstract][Full Text] [Related]
34. B-cell therapy in antineutrophil cytoplasmic antibody-associated vasculitis.
Kallenberg CG; Hauser T
Nephrol Dial Transplant; 2015 Apr; 30 Suppl 1():i119-22. PubMed ID: 25753806
[TBL] [Abstract][Full Text] [Related]
35. Treatment Strategies in ANCA-Associated Vasculitis.
Emejuaiwe N
Curr Rheumatol Rep; 2019 May; 21(7):33. PubMed ID: 31123922
[TBL] [Abstract][Full Text] [Related]
36. 2017 Clinical practice guidelines of the Japan Research Committee of the Ministry of Health, Labour, and Welfare for Intractable Vasculitis for the management of ANCA-associated vasculitis.
Harigai M; Nagasaka K; Amano K; Bando M; Dobashi H; Kawakami T; Kishibe K; Murakawa Y; Usui J; Wada T; Tanaka E; Nango E; Nakayama T; Tsutsumino M; Yamagata K; Homma S; Arimua Y
Mod Rheumatol; 2019 Jan; 29(1):20-30. PubMed ID: 30001655
[TBL] [Abstract][Full Text] [Related]
37. How best to manage relapse and remission in ANCA-associated vasculitis.
Puéchal X; Guillevin L
Expert Rev Clin Immunol; 2022 Nov; 18(11):1135-1143. PubMed ID: 36102147
[TBL] [Abstract][Full Text] [Related]
38. Factors Determining the Clinical Utility of Serial Measurements of Antineutrophil Cytoplasmic Antibodies Targeting Proteinase 3.
Fussner LA; Hummel AM; Schroeder DR; Silva F; Cartin-Ceba R; Snyder MR; Hoffman GS; Kallenberg CG; Langford CA; Merkel PA; Monach PA; Seo P; Spiera RF; William St Clair E; Tchao NK; Stone JH; Specks U;
Arthritis Rheumatol; 2016 Jul; 68(7):1700-10. PubMed ID: 26882078
[TBL] [Abstract][Full Text] [Related]
39. Mycophenolate mofetil vs azathioprine for remission maintenance in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized controlled trial.
Hiemstra TF; Walsh M; Mahr A; Savage CO; de Groot K; Harper L; Hauser T; Neumann I; Tesar V; Wissing KM; Pagnoux C; Schmitt W; Jayne DR;
JAMA; 2010 Dec; 304(21):2381-8. PubMed ID: 21060104
[TBL] [Abstract][Full Text] [Related]
40. Rituximab as an immunosuppressant in antineutrophil cytoplasmic antibody-associated vasculitis.
McGregor JG; Hogan SL; Kotzen ES; Poulton CJ; Hu Y; Negrete-Lopez R; Kidd JM; Katsanos SL; Bunch DO; Nachman PH; Falk RJ
Nephrol Dial Transplant; 2015 Apr; 30 Suppl 1(Suppl 1):i123-31. PubMed ID: 25805743
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
